It appears that a drug to combat C.O.P.D. is just entering the pipeline here in the United States, as Merck & Co. and Nycomed agreed to jointly market Daxas, a once-daily tablet under assessment to treat patients with chronic obstructive pulmonary disease. In a Monday statement, the companies said they would co-promote the drug, generically known as roflumilast, in Canada and certain European countries. And they signed an agreement under which Merck will distribute the drug in the U.K. as well.
In 2009, closely held Nycomed filed a new drug application for Daxas with the U.S. Food and Drug Administration. On April 23, 2010, Nycomed, Zurich, said that a panel within the European Medicines Agency had urged the agency to approve the drug for marketing in the E.U.
For more information contact Senior Solutions at (954) 456-8984 or toll free at 1-800-213-3524
No comments:
Post a Comment